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Wild type HIV-1 protease is a homodimer that plays 
a crucial role in the function of the virus and hence 
has been a target of anti HIV (human immunodefi-
ciency virus) drug design. However, h terodimers 
generated by different mutations in the individual 
monomers have been seen to have different charac-
teristics and thus have been used as macromole ular 
inhibitors of enzyme activity. Further, during the 
course of clinical treatment, it is conceivable that 
more than one mutant species exist inside a cell, re-
sulting in the production of both homo- and het-
erodimers of the enzyme. In this context we have 
investigated here by NMR, the characteristic fea-
tures of a particular heterodimer complexed to the 
peptide inhibitor pepstatin-A. The heterodimer has a 
GGSSG linker joining the two monomers head to tail 
and one of the monomers has a C95M mutation that 
lies in the dimerization domain. NMR backbone as-
signments have revealed that there is an asymmetry 
between the two monomer units. The secondary 
structural characteristics of the protein in the com-
plex are almost identical to those in the crystal struc-
ture of the wild type homodimer protein complexed 
to the inhibitor, acetyl pepstatin. Thus neither the
covalent linker nor the mutation seems to affect the 
gross solution struct ral features of the protease. 
Some local differences are, however, seen near the 
site of mutation. The inhibitor sitting in the active 
site cavity exhibits a flip- op motion. Amide proton 
deuterium exchange studies reveal different local 
stabilities of the individual residues and also differ-
ences between the two monomer units. To our 
knowledge, this is the first NMR report characteriz-
ing a heterodimer of HIV-1 protease and forms a 
basis for future detailed investigation with different 
heterodimers, inhibitors, etc. 
 
HUMAN immunodeficiency virus (HIV) is the etiologi-
cal agent of Acquired Immunodeficiency Syndrome 
(AIDS) and HIV-1 protease is an aspartyl protease that 
catalyses the cleavage of several polypeptides yielding 
mature proteins that are required for the function of the 
virus. Therefore this protein has been the therapeutic 
target for several anti-HIV agents1–3. The functional 
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protease enzyme is a 22 kDa homodimer that self-
assembles from two identical polypeptide chains of 99 
residues each, and resembles other monomeric aspartyl 
proteases4–7. Extensive X-ray crystallographic structural 
studies on the protein and its complexes with a variety 
of inhibitors have been carried out with a view to un-
derstand the molecular mechanisms of inhibition and to 
be able to design better drugs for the dreaded disease 
(reviewed in refs 8–11). The structure of the protein, 
which is seen to be highly conserved, contains a cata-
lytic site at the interface of the two monomers, a flap 
region formed by two loops, one each from the two 
monomers, and the two monomers are held together by 
a short b sheet formed by the amino terminal of one 
monomer and the carboxyl terminal of the other. The 
in ibitor sits in the catalytic site or the active site of the 
enzyme. It has been observed that in the free protein the 
flap is in an open conformation, but gets closed when 
the protein binds to an inhibitor. This suggest  that 
flexibility in the protein conformation plays a major 
role in the functioning of the enzyme.  
The structural studies described above have been the 
basis for design of new inhibitors for the enzyme. Spe-
cific interactions between the protein and different 
types of symmetric and asymmetric inhibitors have been 
investigated, which in turn have suggested possibilities 
for new syntheses. There has been some success in 
these efforts and several drugs have been approved for 
clinical use. However a major hurdle in all these efforts 
has been the emergence of drug-resistant variants of the 
virus12. It has been observed that on continued treatment 
with a particular drug or a combination of drugs, several 
mutations appear in the HIV protease and this depends 
on the length of the treatment13. While many of these 
mutations are at the catalytic site, there are also some at 
places very remote. Wild type and mutant homodimers 
have different activities and binding affinities to inhibi-
tors. Besides, there could be different species in vivo 
with different numbers and types of mutations arising 
out of possible integration of genetically variant14 iral 
DNA into the host chromosomes, and the cellular soup 
may contain both homo- and heterodimers of the prot-
ase enzyme. Thus it follows that the design of drugs 
would have to take care of the additional asymmetry 
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factor, and a lot remains to be investigated, like the ef-
fects of asymmetry in the sequence, asymmetry of in-
ternal motions, asymmetry of interactions and so on.  
The study of heterodimers is significant from another 
point of view. There are reports in the literature, which 
indicate that some of the heterodimers are less active 
compared to the wild type homodimers. The inactivity 
of the het rodimers has been related to instabilities15 in 
the dimerization domains. These have led to artificial 
generation of heterodimers inside the cell as macromo-
lecular inhibitors of viral maturation15–17. Also, single 
site mutations in the heterodimers may aid in the under-
standing of the interactions of inhibitors with the prote-
ase molecule. Thus a detailed knowledge of the 
structure and interactions of heterodimers is of consid-
erable interest for understanding ih bitory actions of 
this dimeric protease. 
In this context, the X-ray structure of a covalently 
tethered dimer–inhibitor complex18 indicates that the 
structure is identical in every respect to that of the wild 
type dimeric molecule, except at the linker region. The 
tethered dimer has also been found to be functionally 
similar to the wild type enzyme19,20. Thus the tethered 
dimer may be a useful surrogate enzyme for studying 
the effects of single site mutations21–23 on substrate and 
inhibitor binding as well as on enzyme asymmetry, and 
for simulating independent mutational drift of the wo
domains, which has been proposed to have led to the 
evolution of modern-day, single-chain aspartic pro-
teinases. Thus we have initiated structural and dynami-
cal studies by NMR on such a tethered dimer which has 
the linker GGSSG joining the two units and a single 
point mutation C95M in the first monomer only. This 
mutation may have significance for the dimerization 
process that is very crucial for the stability and regula-
tion of the wild type protein6,24–26. Also, at this position 
methionine is present in HIV-2 which is homologous to 
HIV-1 (ref. 27). In this paper we report the NMR-
derived features of the tethered heterodimer complexed 
to the general aspartyl protease inhibitor, pepstatin-A1; 
which is a hexapeptide (isovaleryl–Val–Val–Sta–Ala–
Sta), wher  statine (Sta) is the rare amino acid (4S,3S)-
4-amino-3-hydroxy-6-methylheptanoic acid. We present 
our results on secondary structure characterization, lo-
cal stabilities and inhibitor dynamism in the complex. It 
so happens that the NMR spectral dispersion  and pat-
terns are similar to those of complexes of wild type pro-
tein with some other inhibtors, DMP323 and KNI-272 
(refs 28 and 29). This indicates that the gross topology 
of the molecule is conserved. The detailed secondary 
structural characteristics of the protein are seen to be 
similar to those seen in the crystal struc ure of the wild 
type homodimeric protein complexed to a related in- 
hibitor, acetyl pepstatin30. The specific mutation is 
however, seen to introduce some local differences. 
These results provide a basis for future detailed investi-
gations on the protein with different mutations, differ-
ent inhibitors, etc. 
Materials and methods 
Expression of HIV-1 protease tethered dimer 
 
For HIV-1 protease expression, Escherichia coli strain 
BL21 (DE3) transformed with the expression vector 
pET11a containing the gene for HIV-1 protease as 
29 kDa protein was obtained from John W. Erickson, 
NCI-Frederick Cancer Research and Development, 
USA. The uniformly 15N-labelled HIV-1 Protease was 
obtained by growing bacteria at 37°C in M9 minimal 
medium, containing 15NH4Cl (1 g/l) as the sole nitrogen 
source. At an OD600 nm of ~0.6–0.8, protein expression 
was induced by the addition of isopropyl b-D-
thiogalactoside (IPTG) to a final concentration of 
1 mM. After 5 h of further growth at 37°C, cells were 
harvested, washed and stored at –32°C. Uniformly 
13C/15N-labelled HIV-1 protease was obtained by grow-
ing cells in M9 medium containing 15NH4Cl (1 g/l) and 
13glucose (2 g/l) as the sole nitrogen and carbon 
sources, respectively. 
Protein purification 
For HIV-1 protease purification, the frozen cell pellets 
were thawed and resuspended in 15 ml of 10X TE 
buffer (100 mM Tris, 10 mM EDTA, pH 7.5) per litre of 
culture. The cell suspension was kept on ice for 30 min. 
The cells wer  lysed by sonication. The suspension was 
then centrifuged at 12000 g for 15 min at 4°C. The re-
combinant protein was seen to be expressed in inclusion 
bodies, hence was present in the cell pellet. The cell 
pellet was resuspended in 15 ml of 10X TE buffer, 
stirred over an ice-bath for 45 min and then again soni-
cated. This procedure was repeated three times. The 
pellet finally obtained was suspended in 25 ml of 63% 
glacialacetic acid to dissolve inclus on bodies and 
stirred over on ice-bath for 1 h. This suspension was 
subjected to sonication and then centrifug d at 35000 g 
for 1 h at 4°C. The supernatant was diluted 33-fold with 
water, dialysed against water overnight, and dialysed 
against a pH 6.5 buffer consisting of 20 mM Mes, 1 m  
dithiothreitol (DTT), 100 mM NaCl, 5 mM EDTA, 10% 
(vol/vol) glycerol at 4°C for a few hours. During the 
latter dialysis, the 29 kDa polypeptide undergoes 
autolyses to form 22 kDa HIV-1 protease of correct 
amino acid sequence and the precipitate appears in the 
dialysis bag. The precipitate was removed by centrifug-
ing the dialysed solution at 17400 g for 20 min at 4°C 
and pure HIV-1 protease was obtained as supernatant. 
The yield of the protein was 20 mg/l. For NMR sample 
preparation, the protein solution was concentrated and 
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exchanged with pH 5.2 NMR buffer consisting of 
50 mM Na-acetate, 5 mM EDTA, 150 mM DTT by ul-
trafiltration. 
Sample preparation for NMR experiments 
Overall, the stability of the free protein was concentra-
tion-dependent and quite less, just like the wild type 
protease, to record 3D NMR experiments. However, it 
is reported that wild type protease–p p tatin-A complex 
is well formed and stable at pH less than 6.0 (ref. 31). 
Considering this and the fact that the protein is well 
folded at low concentrations, a complex of the het-
erodimeric protein with the inhibitor was formed by 
adding small aliquots (100 ml) of 5 times excess of in-
hibitor dissolved in methanol (4 mg of pepstatin-A dis-
solved in 2 ml of methanol) to the protein solution 
containing protein at mM concentration, pH 5.5 and at 
room temperature. The addition process was completed 
over a period of half to one hour and care was taken that 
the pH of the solution remained between 5.5 and 6.0. 
The solution was incubated at room temperature fo  
about 10–12 h. The solution containing the complex 
was concentrated by ultrafiltration at 4°C. After each 
50 ml reduction in volume, 200 ml of stock solution of 
pepstatin-A was added to the ultrafiltration cell. Since 
the presence of oxygen in the NMR sample tube may 
cause oxidation of cysteine residues, the sample tube 
was well purged with argon gas and another 10–20 ml of 
pepstatin-A stock solution was added before putting the 
protein sample inside the tube. The NMR tube was fi-
nally well sealed with parafilm.  
NMR spectroscopy 
The formation of protein–inhibitor complex did increase 
the protein stability32, which was quite evident by no 
change in the 15N-heteronuclear single quantum correla-
tion (HSQC)33 spectra even after a week. This made it 
possible for us to record a battery of 3D triple reso-
nance experiments, namely HNCA34, HN(CO)CA35, 
CBCANH36, CBCA(CO)NH37 and HNCO34 which are 
essential to correlate backbone 1HN, 15N, 1Ha, 13Ca, 13Cb 
and 13CO spins and also 3D 15N-TOCSY-HSQC38, 15N-
NOESY-HSQC39. All NMR experiments were carried 
out on a Varian Unity+ 600 MHz NMR spectrometer 
equipped with pulsed field-gra ients, using 0.6ml sam-
ples containing 1.0–1.5 mM protein–inhibitor complex 
in NMR buffer at 32°C, in a mixed solvent of 90% H2O 
and 10% D2O. NMR spectra recorded for resonance 
assignments are shown in Table 1. Data transformatio  
and processing were done using the FELIX 97.0 soft-
ware (Molecular Simulations Inc, San Diego, CA). 
Briefly, all the data were apodized with sine squared 
window function shifted by 60° and zero-filled before 
Fourier transformation. In all spectra, 1H, 13C, 15N 
chemical shifts were, respectively, referenced to HDO 
(4.71 ppm at 32°C), indirectly to 2,2-dimethyl-2-
silapentane-5-sulfonic acid (DSS), and to 3-
(trimethylsilyl) propionate sodium (TSP)40. 
Amide proton–deuterium exchange studies were done 
by lyophilizing the protein from the acetate buffer 
(pH 5.2) containing 150 mM DTT and 5 mM EDTA in 
H2O, dissolving the protein in D2O and monitoring the 
signals in a series of two-dimensional 1H–15N HSQC 
spectra. The H/D exchange was monitored till there 
were no visible peaks in the spectrum just above the 
noise level. In each 2D experiment, 32 transients of 
2048 data points were collected for each of the 140 t1 
increments. 
Solvent accessibility calculations 
For the purpose of interpreting amide proton–deuterium 
exchange data, the solvent accessibilities of the individ-
ual residues in the HIV-1–acetyl pepstatin complex
 
 
Table 1.  NMR experiments and their parameters 
 Time domain complex pointsa Spectral width (Hz) 
 
Experiment t1 t2 t3 SW1 SW2 SW3 Matrix sizeb ntc Timed 
 
15N-HSQC 200 (N) 2048 (H) – 2300 8500 – 2048 ´ 4096 8 0.5 
15N-TOCSY-HSQCe 210 (H)  64 (N) 1024 (H) 8500 2300 8500 1024 ´ 128 ´ 1024 12 54.0 
15N-NOESY-HSQCf 210 (H)  64 (N) 1024 (H) 8500 2300 8500 1024 ´ 128 ´ 1024 16 76.0 
HNCA 128 (C)  58 (N) 1024 (H) 5250 2300 8500 256 ´ 128 ´ 1024 12 28.5 
HN(CO)CA  60 (C)  58 (N) 1024 (H) 5250 2300 8500 256 ´ 128 ´ 1024 12 29.0 
HNCO 132 (C)  60 (N) 1024 (H) 2500 2300 8500 256 ´ 128 ´ 1024 8 11.0 
CBCANH 132 (C)  60 (N) 1024 (H) 11500 2300 8500 256 ´ 128 ´ 1024 26 65.0 
CBCA(CO)NH 120 (C)  60 (N) 1024 (H) 11500 2300 8500 256 ´ 128 ´ 1024 26 62.5 
a, N, C, H in the parentheses stand for nitrogen, carbon and proton dimensions, respectively; b, Final matrix size inpoints after 
zero-filling; c, nt is the number of transients for each fid; d, Experimental time in hours; e, TOCSY mixing time used was 68 
ms; f, NOESY mixing time used was 150 ms. 
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Figure 1.  Selected 1H–13Ca strips from the 3D HNCA spectrum at 
32°C of 13C, 15N-labelled protein complexed to pepstatin-A. Sequen-
tial connections from G16 to A22 have been shown. 
crystal structure30 were calculated using the computer 
program NACCESS 2.1.1 (Hubbard, S. J. and Thornton, 
J. M., Department of Biochemistry and Molecular Biol-
ogy, University College London, 1993) which employs 
the Lee–Richards method41.  
Results and discussion 
Backbone assignments and dimer asymmetry 
 
The assignments of the backbone resonances obt ined 
following standard procedures based on triple-
resonance and double-resonance heteronuclear experi-
ments are listed in Table 1. Figure 1 shows an illustra-
tive walk using the HNCA spectrum. Figure 2 shows the 
fingerprint, namely the 1H–15N HSQC spectrum of the 
heterodimer in the complex with residue-specific as-
signments. For many residues pairs of peaks are seen 
which come from the two monomer units. Table 2 lists
 
 
 
 
 
Figure 2.  600 MHz 1H–15N HSQC spectrum at 32°C of uniformly 15N-labelled HIV-1 protease tethered dimer complexed to 
pepstatin-A with residue-specific assignments. 
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Table 2.  Chemical shifts (in ppm) of backbone nuclei of HIV-1 protease tethered dimer complexed to pepsta in-A. Values in parentheses for  
  some residues identify the second set of resonances arising from the asymmetry in the dimer. Linker residues are listed with a prefix L 
Residue 15N HN 13Ca 13Cb 13CO 
 
P1   63.31 
(62.38) 
 
(33.24) 
173.55 
(170.95) 
Q2 121.65 
(120.11) 
8.59 
(8.45) 
55.24 
(55.2) 
32.06 
 
174.98 
 
V3 128.33 
 
9.54 
 
62.05 
 
 176.26 
(176.29) 
T4 116.74 
(116.79) 
8.32 
(8.4) 
61.28 
(61.19) 
  
L5   54.05  176.26 
W6 121.48 7.41 59.48 29.19 175.99 
Q7 114.38 7.47 53.17 31.69 175.88 
R8 121.1 8.71 56.26   
P9   61.92 
(61.94) 
 173.52 
(173.52) 
L10 127.98 
(127.98) 
7.66 
(7.72) 
53.92 
(53.92) 
43.97 
(43.97) 
177.57 
(177.54) 
V11 116.86 
(116.86) 
9.24 
(9.14) 
59.04 
(59.04) 
36.26 
(36.26) 
174.54 
T12 117.28 8.21 62.78 69.75 174.27 
I13 121.58 9.25 58.68 41.45 173.55 
K14 121.05 8.57 55.13 36.03 175.91 
I15 125.44 8.83 59.23 40.76 175.29 
G16 119.62 9.59 47.18  175.5 
G17 106.81 8.71 45.35  173.69 
Q18 120.3 7.98 54.61 31.67 174.28 
L19 123.92 8.37 54.39 43.1 177.49 
K20 122.89 8.86 54.09 37.35 174.25 
E21 121.44 8.55 55.39 32.32 176.32 
A22 126.41 
(125.25) 
9.34 
(9.32) 
50.97 
(50.97) 
24.87 
(24.87) 
173.6 
L23 122.48 8.85 54.0 46.22 176.32 
(176.93) 
L24 125.03 
(125.13) 
8.26 
(8.42) 
54.88 
(54.9) 
 175.91 
D25   53.15  175.91 
T26 114.63 8.42 65.23  175.03 
(175.07) 
G27 112.08 
(111.64) 
9.43 
(7.79) 
45.6 
(45.03) 
 172.32 
(171.52) 
A28 124.16 
(124.16) 
7.29 
(7.41) 
49.41 
(49.49) 
21.95  
D29   57.98 
(57.48) 
42.67 175.12 
D30 113.9 
(112.42) 
6.69 
(6.77) 
52.12 
(51.69) 
45.73 
(45.63) 
172.73 
T31 117.96 8.11 63.58 
(63.32) 
74.0 173.99 
(173.89) 
V32 128.35 
(127.63) 
8.5 
(8.87) 
60.05 
(59.36) 
 173.23 
(172.21) 
L33 127.51 9.38 52.23 45.13 175.12 
E34 116.61 8.14 55.49 
(55.51) 
30.89 175.54 
(174.72) 
E35 116.82 
(116.58) 
7.43 
(7.64) 
58.67 
(58.48) 
30.55 175.79 
(175.62) 
M36 121.0 
(120.75) 
7.02 
(7.07) 
54.88 
(54.88) 
34.49 
(34.49) 
173.52 
 
S37 116.4 8.44 57.7 63.37 173.93 
L38 126.39 7.34 51.99 43.53  
P39   62.92 32.78 177.04 
G40 106.61 8.29 44.69  174.31 
 
 
Residue 15N HN 13Ca 13Cb 13CO 
 
R41 119.59 8.35 56.34 31.53 175.0 
W42 118.91 7.3 53.91 31.45 175.56 
(175.50) 
K43 118.49 
(118.59) 
8.31 
(8.37) 
53.17 
(53.25) 
35.02 
(35.02) 
 
P44   63.25 
(63.32) 
32.96 
(32.96) 
176.52 
(176.46) 
K45 122.51 
(122.59) 
8.59 
(8.51) 
55.5 
(55.96) 
37.21 
(37.05) 
173.81 
(173.81) 
M46 122.29 8.2 54.33 35.02 175.88 
I47 118.53 8.76 59.51  173.72 
G48 109.84 8.36 44.97   
I50   63.79 
(65.86) 
 175.07 
(174.59) 
G51 109.17 
(109.76) 
8.37 
(7.93) 
44.5 
(45.08) 
 173.14 
(173.05) 
G52 106.44 
(106.21) 
7.01 
(7.09) 
44.53 
(44.56) 
 171.3 
F53 119.63 8.44 56.86 
(56.84) 
42.46 176.81 
I54 113.51 
(113.31) 
8.97 
(8.92) 
59.88 
(59.88) 
42.8 173.84 
K55 123.63 8.33 56.18 
(56.39) 
33.47 176.64 
(176.61) 
V56 116.32 8.96 
(8.89) 
58.39 
(58.45) 
35.57 174.89 
(174.89) 
R57 119.49 8.93 55.7 32.63 175.12 
Q58 124.13 9.71 56.0 30.59 174.89 
Y59 129.96 9.25 57.63 41.28 174.37 
D60 121.58 8.8 54.04 43.89 175.15 
Q61 115.08 8.8 56.77 27.02 174.13 
I62 122.55 8.7 57.66 37.07 174.83 
L63 128.23 7.98 59.78 42.92 175.71 
(175.76) 
I64 127.56 
 (127.5) 
9.23 
(9.19) 
59.78 
(59.89) 
42.38 173.69 
E65 125.51 8.38 54.89 
(55.04) 
32.31 
(31.69) 
176.29 
(176.20) 
I66 125.6 
(124.54) 
9.08 
(8.94) 
60.87 
(60.16) 
 175.07 
(174.83) 
C67 126.49 
(125.25) 
9.18 
(9.29) 
59.67 
(59.66) 
27.26 
(26.67) 
175.56 
(175.09) 
G68 105.06 
(104.44) 
8.76 
(8.54) 
45.77 
(45.57) 
 174.07 
(173.86) 
H69 119.64 
(119.64) 
8.21 
(8.09) 
54.66 
(54.71) 
30.17 
(30.42) 
174.31 
(173.99) 
K70 125.43 
(124.38) 
8.85 
(8.78) 
57.56 
(57.05) 
33.72 
(33.14) 
174.92 
 
A71 127.93 8.88 51.0 22.71 174.3 
I72 120.2 8.37 59.18 
(59.22) 
40.72 176.93 
(176.89) 
G73 114.07 
(114.07) 
8.87 
(8.83) 
46.17 
(46.17) 
 171.15 
T74 118.99 
(118.89) 
8.52 
(8.5) 
63.43 
(63.33) 
 175.0 
V75 123.23 8.98 61.09  172.73 
L76 125.14 8.37 52.49 41.79 176.2 
V77 121.1 9.15 60.14 
(60.13) 
 177.19 
(176.99) 
continued 
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Table 2.  Continued 
Residue 15N HN 13Ca 13Cb 13CO 
 
G78 115.0 
(113.82) 
9.13 
(9.02) 
46.11 
(46.11) 
  
P79   63.75 
(63.76) 
28.78 
(32.79) 
175.94 
(175.59) 
T80 120.7 
(120.7) 
8.27 
(8.18) 
57.2 
(54.9) 
  
P81   64.02 
(64.39) 
 175.65 
(175.97) 
V82 114.94 
(116.37) 
7.26 
(7.02) 
59.55 
(60.51) 
35.76 
(37.11) 
173.31 
(174.28) 
N83 124.79 
(125.48) 
8.52 
(8.52) 
54.37 
(54.37) 
38.72  
I84 127.27 9.64 60.95 39.12 174.54 
I85 126.39 9.07 58.55  174.8 
G86 111.64 7.79 44.67  177.16 
R87 116.3 8.95 61.43  176.58 
N88 115.83 7.89 57.14 36.93 175.33 
L89 117.59 7.01 55.64 42.7 178.71 
L90 119.61 8.0 58.22  179.21 
T91 106.24 7.77 63.96 68.17 178.13 
Q92 121.04 6.69 58.1 29.49 
(29.82) 
177.43 
(177.37) 
I93 109.25 
(110.37) 
7.06 
(7.0) 
60.74 
(60.63) 
37.57 
 
174.89 
(175.36) 
G94 108.08 
(108.68) 
7.29 
(7.35) 
46.18 
(46.67) 
 174.25 
(174.77) 
C95(M) 118.91 
(119.71) 
7.29 
(7.59) 
55.69 
(59.03) 
 174.98 
T96 115.0 9.14 59.99  173.72 
L97 120.0 8.3 53.88  176.72 
N98 121.3 8.94 53.34 42.91 172.7 
F99 124.38 8.3 58.52 38.92  
LG1   46.07  174.89 
LG2 109.6 8.35 45.02  175.33 
LS3 116.65 8.51 60.66 63.78 175.44 
LS4 116.0 8.26 57.12 64.28  
 
 
all the residue-specific backbone assignments. Figure 3 
summarizes through-bond backbone connectivities ob-
served in the triple-resonance experiments. The residues 
for which two cross peaks are observed in the 1H–15N 
HSQC spectra are marked by empty circles in Figure 3. 
The heterodimer has two sources of asymmetry, 
namely the linker and the C95M mutation in one of the 
monomers. The linker results in non-equivalence of few 
residues near the N and C terminals of the individual 
monomer units. Since the mutation is also near the C 
terminal, it extends this asymmetry to a few more resi-
dues. The protein–pepstatin-A complex has another 
source of asymmetry, namely the asymmetric inhibitor. 
Thus it must be expected that the interactions of the 
inhibitor with the two monomers would be different and 
one would get different resonances for some residues 
from the two monomers. Indeed we observe from Table 
2 and Figure 2 that for about 20% of the residues we 
have two sets of chemical shifts. Figure 4 shows the 
amide and 15N chemical shift differences of the individ-
ual residues in the two monomer units of the protein in 
the complex. The magnitudes of differences are seen to 
be quite varied and most noteworthy are the changes in 
the catalytic site, e.g. G27.
Chemical shift indices and secondary structure 
The above assignments form the basis for structural and 
dynamic investigations o the protein and its interac-
tions with different inhibitors. Figure 3 also shows the 
chemical shift indices42 for 13Ca, 13Cb and 13CO. A 
negative value in the case of 13Ca and 13CO and a posi-
tive value in the case of 13Cb are indicative of a b-sheet 
backbone conformation. On this basis it is seen from 
Figure 3, that the secondary structure characteristics of 
the heterodimer in solution are very similar to those 
seen in the crystal structure of the complex of wild type 
HIV-1 protease with acetyl-pepstatin. Thus neither the 
linker nor the specific mutation seems to affect the 
gross secondary structural characteristics of the protein. 
One of the two peaks of I93 (Figure 2) is stronger 
than the other, implying that the two amides have dif-
ferent exchange rates with the solvent. This, in turn, 
reflects on different solvent exposures or different 
flexibilities of the two components of the dimerization 
domain. Thus the specific mutation, though does not 
prevent the dimerization process, does introduce some 
local structural differences. 
Deuterium exchange and local stabilities 
H/D exchange studies provide valuable information on 
the local stabilities of individual residues in a given 
protein. Amide proton–deuterium exchange reaction in 
the folded state has been extensively studied for several 
proteins and the process is described by a two-state 
model as follows43–46: 
 
(N–H)cl « (N–H)op ® (N–D). 
 
The protein is believed to be in two sets of conforma-
tions, closed and open, in equilibrium with each other. 
However, solvent exchange occurs only from the open 
stat of the protein. The exchange characteristics are a 
reflection on the solvent accessibilities of the individual 
amide protons in the folded protein on the one hand, 
and on the local stabilities of the conformation on the 
other46. The hydrogen bonded amide protons exchange 
much slower compared to the non-hydrogen bonded 
ones. Thus hydrogen–deuterium (H/D) exchange studies 
give considerable insight into structure, stability, fold-
ing, dynamics and intermolecular interactions in protein 
systems in solution. In favourable situations where pro-
tection factors can be quantitatively measured for a
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Figure 3.  Summary of the through-bond connectivities and chemical shift indices (CSI) iden-
tified for assignment of backbone resances of HIV-1 protease tethered dimer complexed to 
pepstatin-A. Four through-bond correlations between the 15Ni nucleus and 13C nuclei in amino 
acids i and i–1, provided the assignments, as follows: 13Cai in HNCA; 13Cai–1 in HN(CO)CA 
and HNCA; 13Cbi in CBCANH; 13Cbi–1 in CBCA(CO)NH and CBCANH; 13COi–1 in HNCO. 
Solid bars in each row indicate the presence of a cross peak in the spectra for these correla-
tions. The consensus CSI are based on the changes from random-c il v lues for 13Ca, 13Cb and 
13CO. These values are displayed in the bottom row, labelled CSI. A negative value in 13Ca 
and 13CO and a positive value in 13Cb are indicative of a b-sheet backbone conformation. Be-
low CSI are given the secondary structure elements (b-sheet by thick arrow and a-helix by 
cylinder) present in the X-ray crystal structure of HIV-1 protease–acetyl pepstatin complex 
for comparison. The residues where two cross peaks are observed in HSQC spectra are 
marked by empty circles. Filled circles indicate the residues whose amides survived aft r first 
40 minutes after adding D2O. 
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Figure 4.  Residue-wise comparison of the amide proton and amide 15N chemical shift differences between the 
two monomers in protein–pepstatin-A complex. 
 
 
large number of residues, these studies have the poten-
tial of defining the energy landscape of a protein. 
In the present case, considering the asymmetry in the 
structure in some regions of the protein– epstatin-A 
complex (refer to Table 2 of supplementary material), 
one could in principle monitor H/D exchange kinetics of 
124 backbone amide protons (see Figure 2). However, 
of these, only 24 were seen to survive after the first 40 
minutes after addition of D2O, 18 survived after 
140 minutes and so on, as shown in Figure 5 a. This 
directly displays the variation of exchange time along 
the polypeptide chain. Four residues, namely V32, E34, 
A71 and V75 are protected till 26 h. The other 20 amide 
protons which do not exchange out in the first 40 min-
utes are L10, V11, I13, K20, A22, L23, A28, L33, V56, 
Q58, I62, I64, E65, I66, G73, L76, V77, G78, I84 and 
I85. The residues indicated in bold are those for which 
separate peaks are seen for the two monomer units, but 
only one of them is retained in the H/D exchange ex-
periments. A quantitative characterization of the ex-
change kinetics was not feasible because of insufficient 
time resolution in the data. However, useful qualitative 
information on the local stabilities of the heterodimeric 
protein has been derived as described next in the article. 
Taking the X-ray structure of HIV-1 protease with 
acetyl pepstatin to be a valid solution structure for the 
present system, the differently exchanging residues are 
shown in a colour-coded manner in Figure 6. It is seen 
that ev n some of the residues involved in b-sheet con-
formation also exchange significantly within one hour. 
This includes Q2 to L5, K43 to G49, G52 to K55, H69, 
K70, C95 to F99. These residues belong to the dimeri-
zation domain (Q2–L5, C95–C99), hinge region (K43–
G49) and flap regions (G52–K 5), respectively. This is 
significant considering that the dimerization domain is 
believed to be playing an important role in the control 
mechanism of the enzyme and the hinge and flap re-
gions are important for inhibitor binding. 
The amide proton–deuterium exchange results have to 
be interpreted by first considering their solvent accessi-
bilities in the structure and then in terms of the local 
stabilities. To this end, we calculated the solvent acces-
sibilities of the main chain atoms of the individual resi-
dues from the crystal structure as mentioned in 
Mat rials and methods section. Data are also shown in 
Figure 5 b. We see a wide variation in the solvent ac-
cessibilities among the different residues and also dif-
ferenc s are seen between the two monomer units. The 
peaks which are seen in the H/D exchange spectra are 
those for which the solvent accessibility is nearly zero, 
except in L10, for which the accessibility value is 69.5. 
This peak should have been absent in the H/D exchange
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Figure 5.  a, Variation of the exchange time along the polypeptide chain in amide proton–deuterium exchange 
experiments. Residues for which only one peak is seen in the exchange experiment (D2O 15N-HSQC) as 
against two in H2O 15N-HSQC have an asterisk (*) on top of the bar; b, Relative solvent accessibilites of the 
residues calculated using the X-ray structure of HIV-1 protease–acetyl pepstatin complex in both chains.
c, Difference plot of solvent accessibilities to indicate the residues protected by the inhibitor (see text). 
 
a 
b 
c 
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Figure 6.  Residues retained during the amide proton–deuterium exchange experiments are shown in colour-
coded manner. Residues which survive for 0.7 h from the start of experiment are shown in red, for 4.3 h in 
yellow, for 18 h in green and for 21 h in grey. Smaller size of the ball within a given set indicates that only 
one peak is seen in the experiment compared to the two peaks present in H2O 15N-HSQC. 
 
spectra. Though the solvent accessibilities are nearly 
zero for all the residues retained in H/D exchange spec-
tra, there is ubstantial gradation in their retention 
times. Similarly, for residues 3, 7, 15, 18, 26, 30, 31, 
43, 45, 47, 48, 54, 57, 59, 69, 76, 82, 83, 86, 87, 89, 90, 
96 and 97 the solvent accessibility values are nearly 
zero, but they are not seen in the H/D exchang  spectra. 
These residues are well protected, but show high ex-
change rates. These differences could either mean that 
the solution structure is different from the crystal struc-
ture or that there is a high degree of open–close local 
flexibility in the structure. The secondary structural 
information derived from the chemical shift indices data 
described earlier, shows a close parallel with the X-ray 
structure, and hence it is reasonable to think that the 
overall fold and tertiary structures in solution and crys-
tal are also not very different. Moreover, in a large 
number of structures with different inhibitors, muta-
tions, etc. which have been reported in the literatur , the 
backbones of the polypeptide chains are nearly super-
imposable8. Thus the above discrepancies between sol-
vent accessibilities and exchange results must be 
interpreted in terms of the different degrees of local 
stabilities in the molecule. The highly protected resi-
dues V32, E34, A71 and V75 must have very rigid 
structures. 
We notice that for 10 residues, L10, V11, A22, A28, 
V56, I64, I66, G73, G78, where two sets of peaks are 
seen in the H2O spectra, only one of them is seen in the 
H/D exchange spectra. Since the solvent accessibilities 
for all of these in both the monomers are zero, except 
for L10, which anyway does not have good correlation 
with solvent accessibility, this difference must indicate 
differences in the local open–close conformational 
flexibilities in the two monomer units. Interestingly, 
these are distributed throughout the sequence of the 
polypeptide chain. Thus while the chemical shift data 
identify the asymmetry in the structure, the H/D ex-
change data identify the asymmetry in the stabilities in 
the two monomer units. 
In order to probe the active site directly and to evalu-
ate the contribution of the inhibitor to amide protection, 
we removed the inhibitor coordinates from the crystal 
structure coordinates of the complex and again calcu-
lated the solvent accessibilities. A difference plot of the 
solvent accessibilities with and without the inhibitor is 
shown in Figure 5 c. We notice that six residues are 
well protected (two of them, G27 and G48 more signifi-
cantly) by the inhibitor. The H/D exchange data, how-
ever, show a remarkable difference. One would have 
expected the above residu  to be slowly exchanging. In 
contrast, they exchange out within the first 40 minutes 
indicating, as mentioned earlier, a high degree of local 
flexibility in the active site (G27) and flap region (G48) 
of the complex. The above amide peaks are also weak in 
the H2O spectrum, which supports the above conclusion. 
Flip-flop motion of inhibitor in the complex 
During the course of the assignments, we observed 
cross peaks between the amide protons of V82 in the
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Figure 7.  Strips from a 3D 15N-separated 600-MHz NOESY spec-
trum of the protease complexed to pepstatin-A at the 15N chemical 
shifts of (a) E35 and (b) V82 residues. Left and right panels contain 
the peaks from the individual monomers and the connec ions drawn 
identify chemical exchange cross peaks (*) arising due to dynamism 
of pepstatin-A in the active site. 
 
 
two monomers and also between the amide protons of 
E35 in the 15N edited NOESY spectrum (Figure 7). In 
the crystal structure of the complex between acetyl pep-
statin and homodimeric protease, the distance between 
the V82 amide protons is 17.5 Å and that between the 
amide protons of E35 is 29 Å. Therefore, an NOE cross 
peak between the two sets of amide protons is not po-
sible. Similar NOE cross peaks were also observed in 
the case of the homodimer–KNI-529 (a variant of KNI-
272) complex and the peaks were attributed to be origi-
nating from chemical exchange due to a flip-flop mo-
tion of the inhibitor. On the basis of the temperature 
dependence of the exchange rates in KNI-529 complex47 
and the measured enthalpy changes by calorimetric 
methods in the case of acetyl pepstatin complex48, it 
was concluded that the inhibitor KNI-529 undergoes the 
flip-flop motion in the cavity of the enzym  without 
dissociating from the complex47. We believe that similar 
conclusions would be applicable to pepstatin-A as well, 
in the present situation. 
The flip-flop motion and the associated conforma-
tional transitions would influence the widths of the 
resonances and could result in non-observation of some 
peaks in the spectra. Specifically, we could not observe 
the amide-15N cross peaks of residues D25, D29, G49 
and I50 in the HSQC spectra of the complex. The first 
two of these residues are located in the active site, while 
the other two are in the flap.  
Concluding remarks 
Structure, stability, inhibitor binding and dynamical 
characteristics of HIV-1 protease continue to draw wide 
attention in the literature11,26,29,31,47–49,50–53. While NMR 
is the most suited technique for such investigations, 
these studies have not been as extensive as the X-ray 
crystallographic studies. Further, from the point of view 
investigating the roles of individual monomer units in 
enzyme action and consequently from the viewpoint of 
drug design, the tethered dimers show great promise. 
They permit creation of monomer-specific mutations in 
the dimeric structure. In this context, we have described 
in this paper qualitative characterization of secondary 
structure and local stabilities in a tethered heterodimer 
of HIV-1 protease complexed to the general aspa tyl 
protease inhibitor, pepstatin-A, by NMR spectroscopy. 
We observed that the mutation did not prevent proper 
dimer formation, but did influence the dynamical prop-
erties of the neighbouring residues. The NMR chemical 
shift indices indicated that the secondary structure ele-
ments of the heterodimer protein in the complex were 
similar to those in the crystal structure of the 
homodimer–acetyl pepstatin complex. Amide proton–
deuterium exchange studies, in conjunction with solvent 
accessibility calculations indicated different local st-
bilities in different regions of the protein in the complex 
and also indicated differences in the two monomer 
units. The NOE data on the complex showed exchange 
cross peaks between the amide protons of V82 and E35 
residues in the individual monomers and these were 
attributed to a flip- op dynamic motion of the inhibitor 
in the complex. These observed dynamisms in the pro-
tein and the inhibitor, reflect on the ability of the pro-
tein to accommodate different types of inhibitors/ 
substrates. Thus, one may speculate that for a drug 
binding at the active site to be efficient, it may be nec-
essary not only to have a high binding affinity but also 
to induce high rigidity in the structure or it should be 
able to adjust itself to the demans of a mutated protein. 
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